Encorafenib(Braftovi)

Encorafenib is a prescription drug approved for marketing by the U.S. Food and Drug Administration (FDA) in 2018. It is indicated for BRAF V600E and BRAF V600K gene mutations confirmed by an FDA-approved test, and must be used strictly in accordance with medical advice.

Targets of Action

BRAF V600E and BRAF V600K gene mutations (confirmation via an FDA-approved test is required).

Mechanism of Action

Encorafenib can inhibit the proliferation of tumor cell lines expressing BRAF V600E, V600D and V600K mutations in vitro.

Dosage and Administration

Route and frequency of administration for Encorafenib: Oral administration, once daily.

The dosage of Encorafenib needs to be adjusted according to the patient's actual condition; for specific details, patients should consult their physicians and follow medical advice strictly.

Recommended reading: Dosage and Administration of Encorafenib

Adverse Reactions

Common adverse reactions: Dizziness, syncope.

Serious adverse reactions: Risk of new primary skin cancer, cardiac disorders, hepatic disorders, myopathy, etc.

Reference article: Adverse Reactions of Encorafenib

Use in Special Populations

Infertility: Encorafenib is a prescription drug. Male patients of childbearing potential should be informed that this drug may impair fertility, and its use must be in accordance with medical advice.

Lactation: It is recommended that women do not breastfeed during treatment with Encorafenib in combination with Binimetinib and for 2 weeks after the last dose.

General Precautions

1. If a dose of Encorafenib is missed by more than 12 hours, or vomiting occurs after administration, no additional dose is needed; the next scheduled dose should be taken as usual.

2. Risk of new primary malignant neoplasms: Patients are advised to contact their attending physician immediately if new skin lesions appear, existing skin lesions change, or other signs and symptoms of malignant neoplasms develop.

3. Bleeding risk: Patients are advised to contact a physician and seek emergency medical care immediately if signs and/or symptoms of abnormal bleeding occur (e.g., headache, dizziness, fatigue, bloody stool, hemoptysis, hematemesis).

FDA，2025.03